Biomerica, Inc.
BMRA · NASDAQ
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -10.13 | -0.04 | -0.97 | 0.48 |
| FCF Yield | -3.24% | -2.23% | -1.04% | -1.48% |
| EV / EBITDA | 52.14 | -18.95 | -88.35 | -52.04 |
| Quality | ||||
| ROIC | -8.09% | -34.39% | -19.84% | -17.25% |
| Gross Margin | 30.72% | -32.58% | 1.70% | 26.71% |
| Cash Conversion Ratio | -134.00 | 0.43 | 0.90 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.38% | -0.18% | -15.86% | -29.75% |
| Free Cash Flow Growth | 59.46% | 36.75% | -32.11% | 41.15% |
| Safety | ||||
| Net Debt / EBITDA | -25.05 | 1.33 | 2.26 | 1.76 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.65 | 0.67 | 0.66 | 0.67 |
| Cash Conversion Cycle | 153.15 | 196.15 | 185.68 | 207.23 |